Hyperbaric oxygen therapy for late radiation tissue injury

Department of Diving and Hyperbaric Medicine, Prince of Wales Hospital, Barker Street, Randwick, New South Wales, Australia, 2031.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 02/2005; 5(3):CD005005. DOI: 10.1002/14651858.CD005005.pub2
Source: PubMed


There is a risk of serious complications developing after radiation treatment for cancer (late radiation tissue injury (LRTI). Hyperbaric oxygen therapy (HBOT) involves breathing oxygen in a specially designed chamber. It is used as a treatment to improve oxygen supply to damaged tissue and stimulate healing. We found some evidence that LRTI affecting the head, neck and lower end of the bowel can be improved with HBOT. There is little evidence for or against benefit in other tissues affected by LRTI. Our conclusions are based on eight randomised trials with a limited number of patients. Further research is needed.

Download full-text


Available from: Michael Bennett
  • Source
    • "We also postulated that HBOT may result in accelerated healing of injured tissues because it is thought that HBOT improves oxygen supply to wounds and therefore improves their healing. Again, there is no evidence supporting the HBOT in the management of patients with radiation-induced pelvic soft tissue necrosis including proctitis[6]. As there is no standardized treatment for a BT-induced RUF the responsibility for treatment is borne by the physicians in charge. "

    Full-text · Dataset · Jan 2016
  • Source
    • "HBO 2 treatment involves breathing 100% O 2 at 2 to 3 atmospheres absolute (ATA) pressure for 1.5 to 2 h once or twice daily. HBO 2 has been shown to improve refractory diabetic wounds and delayed radiation injuries in randomized trials and use is supported by independent evidencebased reviews (Bennett et al., 2008; Clarke et al., 2008; Kranke et al., 2012; Goldman, 2009; Fife et al., 2007; Duzgun et al., 2008; Londahl et al., 2010). Several studies have failed to identify clinical efficacy (Annane et al., 2004; Margolis et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Because hyperbaric oxygen treatment mobilizes bone marrow derived-stem/progenitor cells by a free radical mediated mechanism, we hypothesized that there may be differences in mobilization efficiency based on exposure to different oxygen partial pressures. Blood from twenty consecutive patients was obtained before and after the 1st, 10th and 20th treatment at two clinical centers using protocols involving exposures to oxygen at either 2.0 or 2.5 atmospheres absolute (ATA). Post-treatment values of CD34+, CD45-dim leukocytes were always 2-fold greater than the pre-treatment values for both protocols. Values for those treated at 2.5 ATA were significantly greater than those treated at 2.0 ATA by factors of 1.9 to 3-fold after the 10th and before and after the 20th treatments. Intracellular content of hypoxia inducible factors -1, -2, and -3, thioredoxin-1 and poly-ADP-ribose polymerase assessed in permeabilized CD34+ cells with fluorophore-conjugated antibodies were twice as high in all post- versus pre-treatment samples with no significant differences between 2.0 and 2.5 ATA protocols. We conclude that putative progenitor cell mobilization is higher with 2.5 versus 2.0 ATA treatments, and all newly mobilized cells exhibit higher concentrations of an array of regulatory proteins.
    Full-text · Article · Feb 2014 · Stem Cell Research
  • Source
    • "Gastroenterology Research and Practice with PRD who were resistant to conventional oral or topical treatments [6] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pelvic radiation disease (PRD) occurs in 2-11% of patients undergoing pelvic radiation for urologic and gynecologic malignancies. Hyperbaric oxygen therapy (HBOT) has previously been described as a noninvasive therapeutic option for the treatment of PRD. the purpose of study was to analyze prospectively the results of HBOT in 44 consecutive patients with PRD who were resistant to conventional oral or topical treatments. Material and Methods. The median age of the cohort was 65.7 years (39-85). Twenty-seven percent of patients required blood transfusion (n = 12). The median of delay between radiotherapy and HBOT was 26 months (3-175). We evaluated the results of HBOT, using SOMA-LENT Scale. Results. SOMA-LENT score was decreased in 59% of patient. The median of SOMA-LENT score before HBOT was significantly higher, being equal to 14 (0-36), than after HBOT with the SOMA-LENT score of 12 (0-38) (P = 0.003). Tenesmus (P = 0.02), bleeding (P = 0.0001), and ulceration (P = 0.001) significantly decreased after HBOT. Regarding patients with colostomy, 33% (n = 4) benefited from colostomies closure. HBOT was generally well tolerated. Only one patient stopped precociously due to transient myopia. Conclusion. This study is in favor of the interest of HBOT in pelvic radiation disease treatment (PRD).
    Full-text · Article · Jan 2014 · Gastroenterology Research and Practice
Show more